SeaStar Medical Announces 1-for-10 Reverse Split, Shares Drop 9.5%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 24 2025
0mins
Source: Benzinga
- Reverse Split Impact: SeaStar Medical's announcement of a 1-for-10 reverse split led to a 9.5% drop in pre-market trading, bringing the share price down to $0.21, reflecting market concerns about the company's future prospects.
- Market Reaction: Following the reverse split news, SeaStar's stock price quickly declined, indicating a lack of investor confidence in the company's financial health, which could affect its ability to raise capital and its market image.
- Other Stock Movements: Coincheck Group NV and Ascent Solar Technologies also saw declines in pre-market trading, dropping 11% and 7.6% respectively, indicating a broader bearish sentiment in the market that may influence investor risk appetite.
- Industry Trends: In light of the market's reaction to the reverse split, SeaStar Medical may need to reassess its capital structure and future strategy to restore investor confidence and improve stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICU
Wall Street analysts forecast ICU stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.660
Low
1.00
Averages
1.00
High
1.00
Current: 3.660
Low
1.00
Averages
1.00
High
1.00
About ICU
SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SeaStar Medical Reports Q1 2026 Earnings Highlights
- Customer Expansion Progress: In Q1 2026, SeaStar Medical successfully attracted 7 new hospitals to adopt QUELIMMUNE therapy, representing a nearly 70% increase from Q1 2025, which not only enhances market penetration but also lays the groundwork for achieving the goal of 15 new customers this year.
- Significant Revenue Growth: QUELIMMUNE's net revenue reached $495,000 in the first quarter, a 69% increase from the same period last year, indicating a rebound in customer orders that is expected to drive the company closer to its revenue target of approximately $2 million for 2026.
- Clinical Trial Progress: Currently, the NEUTRALIZE-AKI trial has enrolled 198 patients out of a planned total of 339, with completion expected by the end of 2026, paving the way for future market opportunities and potentially reporting top-line results in mid-2027.
- Regulatory Pathway Optimization: The company is discussing a modular PMA submission for the adult AKI indication with the FDA to expedite the approval process, while also seeking to transition the SAVE Registry from mandatory to voluntary post-marketing study to reduce administrative burdens on children's hospitals and facilitate broader adoption of QUELIMMUNE.
See More
SeaStar Medical Reports Q1 2026 Earnings Results
- Earnings Report: SeaStar Medical's Q1 2026 GAAP EPS of -$0.90 missed expectations by $0.08, indicating challenges in profitability that could affect investor confidence.
- Revenue Growth: The company reported revenue of $0.49 million, beating estimates by $0.05 million, suggesting that despite overall profitability issues, SeaStar has achieved some revenue growth, potentially laying a foundation for future business development.
- Cash Flow Status: As of March 31, 2026, the company's cash reserves stood at $9.3 million, down from $12.0 million as of December 31, 2025, reflecting potential pressures in operational funding management and raising concerns about liquidity risk.
- Market Reaction: Given the reported losses and cash decline, market reactions to SeaStar Medical may lean towards caution, prompting investors to closely monitor subsequent financial performance and strategic adjustments.
See More
SEASTAR MEDICAL HOLDING CORP - PROSPECTUS FOR THE RESALE OF UP TO 2 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDER
Company Overview: SeaStar Medical Holding Corp is involved in the sale of up to 2 million shares of its common stock.
Stockholder Action: The sale is being conducted by selling stockholders, indicating a potential shift in ownership or investment strategy.
See More
SeaStar Medical Presents New Therapy Data at AKI Conference
- Therapy Efficacy Validation: SeaStar Medical's QUELIMMUNE SAVE Registry data presented at the AKI & CRRT 2026 conference indicates no device-related adverse events among the first 21 pediatric patients treated with the Selective Cytopheretic Device (SCD), achieving a 76% survival rate at Day 28 and Day 60, and 71% at Day 90, demonstrating an approximate 50% reduction in mortality compared to historical data, validating the therapy's effectiveness.
- Immunomodulatory Mechanism: Research shows that SCD therapy modulates the immune response by shifting pro-inflammatory monocytes to an anti-inflammatory reparative phenotype, potentially counteracting the hyperinflammation that drives organ failure in AKI, thereby enhancing the clinical applicability of the therapy.
- Educational Symposium Held: SeaStar Medical hosted an educational symposium featuring leading pediatric nephrology experts during the conference, introducing the first Advanced Practice Provider Panel to support broader adoption of QUELIMMUNE, reflecting the company's commitment to promoting the new therapy's accessibility.
- Adult Trial Advancement: The company is advancing its NEUTRALIZE-AKI pivotal trial targeting AKI in adults, a condition affecting over 200,000 adults annually in the U.S. with no effective treatment options, highlighting SeaStar Medical's strategic significance in addressing a critical market need.
See More
SeaStar Medical Presents SAVE Registry Data on Pediatric AKI Treatment
- SAVE Registry Data Released: SeaStar Medical presented new SAVE Registry data at the International Conference on Advances in Critical Care Nephrology, revealing no device-related adverse events in pediatric patients treated with SCD, with survival rates of 69% at both Day 28 and Day 60, indicating the therapy's effectiveness and safety in clinical settings.
- Immunomodulation Research Advances: In vitro analysis demonstrates that the Selective Cytopheretic Device (SCD) can shift monocytes towards an anti-inflammatory and reparative phenotype, further validating the device's potential in modulating immune responses and offering new solutions for treating hyper-inflammatory states.
- Successful Industry Symposium: The symposium hosted by SeaStar Medical attracted leading experts in pediatric Acute Kidney Injury (AKI) to discuss the role of SCD technology in modulating immune cells, enhancing the company's leadership position in the field and promoting broader adoption of QUELIMMUNE therapy.
- Future Development Outlook: SeaStar Medical's QUELIMMUNE therapy received FDA approval in 2024 for critically ill pediatric patients with AKI and sepsis, expected to significantly reduce patient mortality rates and further solidify the company's market position in pediatric nephrology treatment.
See More
SeaStar Medical Reports Improved Q4 Results with Revenue Growth
- Performance Improvement: SeaStar Medical's Q4 net loss narrowed to $2.90 million, or $0.80 per share, from $4.41 million and $8.98 per share last year, indicating a significant improvement in financial health.
- Revenue Growth: The company reported net revenue of $420,000 in Q4, a substantial increase from $67,000 a year ago, primarily driven by sales of QUELIMMUNE, reflecting rising market acceptance.
- Clinical Trial Progress: The NEUTRALIZE-AKI pivotal trial has enrolled 181 adult AKI patients out of a target of 339, achieving over 50% enrollment, which is expected to facilitate the application of SCD therapy in the adult market.
- Future Outlook: SeaStar Medical plans to expand QUELIMMUNE adoption to 15 top-ranked children's medical centers by 2026, anticipating approximately $2 million in net product revenue, demonstrating confidence in future growth.
See More
SeaStar Medical Reports Q1 2026 Earnings Highlights
- Customer Expansion Progress: In Q1 2026, SeaStar Medical successfully attracted 7 new hospitals to adopt QUELIMMUNE therapy, representing a nearly 70% increase from Q1 2025, which not only enhances market penetration but also lays the groundwork for achieving the goal of 15 new customers this year.
- Significant Revenue Growth: QUELIMMUNE's net revenue reached $495,000 in the first quarter, a 69% increase from the same period last year, indicating a rebound in customer orders that is expected to drive the company closer to its revenue target of approximately $2 million for 2026.
- Clinical Trial Progress: Currently, the NEUTRALIZE-AKI trial has enrolled 198 patients out of a planned total of 339, with completion expected by the end of 2026, paving the way for future market opportunities and potentially reporting top-line results in mid-2027.
- Regulatory Pathway Optimization: The company is discussing a modular PMA submission for the adult AKI indication with the FDA to expedite the approval process, while also seeking to transition the SAVE Registry from mandatory to voluntary post-marketing study to reduce administrative burdens on children's hospitals and facilitate broader adoption of QUELIMMUNE.
See More
SeaStar Medical Reports Q1 2026 Earnings Results
- Earnings Report: SeaStar Medical's Q1 2026 GAAP EPS of -$0.90 missed expectations by $0.08, indicating challenges in profitability that could affect investor confidence.
- Revenue Growth: The company reported revenue of $0.49 million, beating estimates by $0.05 million, suggesting that despite overall profitability issues, SeaStar has achieved some revenue growth, potentially laying a foundation for future business development.
- Cash Flow Status: As of March 31, 2026, the company's cash reserves stood at $9.3 million, down from $12.0 million as of December 31, 2025, reflecting potential pressures in operational funding management and raising concerns about liquidity risk.
- Market Reaction: Given the reported losses and cash decline, market reactions to SeaStar Medical may lean towards caution, prompting investors to closely monitor subsequent financial performance and strategic adjustments.
See More
SEASTAR MEDICAL HOLDING CORP - PROSPECTUS FOR THE RESALE OF UP TO 2 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDER
Company Overview: SeaStar Medical Holding Corp is involved in the sale of up to 2 million shares of its common stock.
Stockholder Action: The sale is being conducted by selling stockholders, indicating a potential shift in ownership or investment strategy.
See More
SeaStar Medical Presents New Therapy Data at AKI Conference
- Therapy Efficacy Validation: SeaStar Medical's QUELIMMUNE SAVE Registry data presented at the AKI & CRRT 2026 conference indicates no device-related adverse events among the first 21 pediatric patients treated with the Selective Cytopheretic Device (SCD), achieving a 76% survival rate at Day 28 and Day 60, and 71% at Day 90, demonstrating an approximate 50% reduction in mortality compared to historical data, validating the therapy's effectiveness.
- Immunomodulatory Mechanism: Research shows that SCD therapy modulates the immune response by shifting pro-inflammatory monocytes to an anti-inflammatory reparative phenotype, potentially counteracting the hyperinflammation that drives organ failure in AKI, thereby enhancing the clinical applicability of the therapy.
- Educational Symposium Held: SeaStar Medical hosted an educational symposium featuring leading pediatric nephrology experts during the conference, introducing the first Advanced Practice Provider Panel to support broader adoption of QUELIMMUNE, reflecting the company's commitment to promoting the new therapy's accessibility.
- Adult Trial Advancement: The company is advancing its NEUTRALIZE-AKI pivotal trial targeting AKI in adults, a condition affecting over 200,000 adults annually in the U.S. with no effective treatment options, highlighting SeaStar Medical's strategic significance in addressing a critical market need.
See More
SeaStar Medical Presents SAVE Registry Data on Pediatric AKI Treatment
- SAVE Registry Data Released: SeaStar Medical presented new SAVE Registry data at the International Conference on Advances in Critical Care Nephrology, revealing no device-related adverse events in pediatric patients treated with SCD, with survival rates of 69% at both Day 28 and Day 60, indicating the therapy's effectiveness and safety in clinical settings.
- Immunomodulation Research Advances: In vitro analysis demonstrates that the Selective Cytopheretic Device (SCD) can shift monocytes towards an anti-inflammatory and reparative phenotype, further validating the device's potential in modulating immune responses and offering new solutions for treating hyper-inflammatory states.
- Successful Industry Symposium: The symposium hosted by SeaStar Medical attracted leading experts in pediatric Acute Kidney Injury (AKI) to discuss the role of SCD technology in modulating immune cells, enhancing the company's leadership position in the field and promoting broader adoption of QUELIMMUNE therapy.
- Future Development Outlook: SeaStar Medical's QUELIMMUNE therapy received FDA approval in 2024 for critically ill pediatric patients with AKI and sepsis, expected to significantly reduce patient mortality rates and further solidify the company's market position in pediatric nephrology treatment.
See More
SeaStar Medical Reports Improved Q4 Results with Revenue Growth
- Performance Improvement: SeaStar Medical's Q4 net loss narrowed to $2.90 million, or $0.80 per share, from $4.41 million and $8.98 per share last year, indicating a significant improvement in financial health.
- Revenue Growth: The company reported net revenue of $420,000 in Q4, a substantial increase from $67,000 a year ago, primarily driven by sales of QUELIMMUNE, reflecting rising market acceptance.
- Clinical Trial Progress: The NEUTRALIZE-AKI pivotal trial has enrolled 181 adult AKI patients out of a target of 339, achieving over 50% enrollment, which is expected to facilitate the application of SCD therapy in the adult market.
- Future Outlook: SeaStar Medical plans to expand QUELIMMUNE adoption to 15 top-ranked children's medical centers by 2026, anticipating approximately $2 million in net product revenue, demonstrating confidence in future growth.
See More
